Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: Study design

BMC Nephrology

Volumn 12, Issue 1, 2011, Pages

  Trachtman, Howard ^a   Vento, Suzanne ^a   Gipson, Debbie ^b   Wickman, Larysa ^b   Gassman, Jennifer ^c   Joy, Melanie ^d   Savin, Virginia ^e   Somers, Michael ^f   Pinsk, Maury ^g   Greene, Tom ^h  

^a Hofstra Northwell Steven and Alexandra Cohen Children s Medical Center of NY Northwell Health   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g UNIVERSITY OF ALBERTA   (Canada)

^h UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ATORVASTATIN; GALACTOSE; LISINOPRIL; LOSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PYRROLE DERIVATIVE;

ARTICLE; CONSERVATIVE TREATMENT; CREATININE URINE LEVEL; DRUG EFFICACY; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; TREATMENT RESPONSE; ADOLESCENT; ADULT; CHILD; CLINICAL TRIAL; DRUG COMBINATION; DRUG RESISTANCE; FOLLOW UP; HUMAN; INFANT; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GALACTOSE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEPTANOIC ACIDS; HUMANS; INFANT; LISINOPRIL; LOSARTAN; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79751537562     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-12-8     Document Type: Article

References (50)

1. Management of focal segmental glomerulosclerosis: Evidence-based recommendations. E Burgess, Kidney Int 1999 55 26 S32 10.1046/j.1523-1755.1999. 07004.x
2. Focal segmental glomerulosclerosis: pathogenesis and treatment. C Ben (Pubitemid 36337828)
3. Angiotensin-converting enzyme inhibition and progression of renal disease. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. TH Jafar PC Stark CH Schmid for the AIPRD Study Group, et al. Kidney Int 2001 60 1131 40 10.1046/j.1523-1755.2001.0600031131.x 11532109 (Pubitemid 34205814)
4. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. RT Gansevoort WJ Sluiter MH Hemmelder D de Zeeuw PE de Jong, Nephrol Dial Transplant 1995 10 1963 74 8643149
5. Enalapril: Antiproteinuric effect in children with nephrotic syndrome. G Lama I Luongo A Piscitelli ME Salsano, Clin Nephrol 2000 53 432 6 10879662 (Pubitemid 30390072)
6. Angiotensin converting enzyme inhibitors and angiotensin receptor (AT1) antagonists: Either or both for primary renal disease? K McLaughlin AG Jardine, Nephrol Dial Transplant 1999 14 25 8 10.1093/ndt/14.1.25 10052468 (Pubitemid 29041858)
7. Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome. DS Milliner BZ Morgenstern, Pediatr Nephrol 1991 5 587 90 10.1007/BF00856646 1911144
8. ACE-inhibitors: Panacea for progressive renal disease? G Navis D de Zeeuw PE de John, Lancet 1997 349 1852 3 10.1016/S0140-6736(97)22026-X 9217751 (Pubitemid 27270113)
9. Long-term therapy with enalapril in patients with nephrotic-range proteinuria. W Proesmans I Van Wambeke M Van Dyck, Pediatr Nephrol 1996 10 587 9 10.1007/s004670050166 8897561 (Pubitemid 26331768)
10. Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: A retrospective study in a single clinic. KP Stiles KC Abbott PG Welch CM Yuan, Clin Nephrol 2001 56 89 95 11522100 (Pubitemid 32707816)
11. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. D Russo R Minutolo A Pisani R Esposito G Signoriello M Andreucci MM Balletta, Am J Kidney Dis 2001 38 18 25 10.1053/ajkd.2001.25176 11431176 (Pubitemid 32611753)
12. ACEi/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. KT Woo YK Lau KS Wong GS Chiang, Kidney Int 2000 58 2485 91 10.1046/j.1523-1755.2000.00432.x 11115082
13. effect of lipoid reduction on progression of renal disease: A meta-analysis. L Fried TJ Orchard BL Kasiske for the Lipids and renal Disease Progression Meta-Analysis Study Group, Kidney Int 2001 59 260 9 10.1046/j.1523-1755.2001.00487.x 11135079 (Pubitemid 32055234)
14. the future of renoprotection: frustration and promises. A Schieppati G Remuzzi, Kidney Int 2003 63 1947 55 10.1046/j.1523-1755.2003.00340.x (Pubitemid 37449529)
15. Retarding the progression of renal disease. BM Brenner, Kidney Int 2003 63 370 8 10.1046/j.1523-1755.2003.t01-2-00052.x
16. How to fully protect the kidney in a more severe model of progressive nephropathy: a multidrug approach. C Zoja D Corna D Camozzi D Cattaneo, et al. J Am Soc Nephrol 2002 13 2898 908 10.1097/01.ASN.0000034912.55186.EC 12444208 (Pubitemid 35386909)
17. Renoprotection: One or many therapies? LA Hebert WA Wilmer ME Falkenhain SE Ladson-Wofford S Nahman BH Rovin, Kidney Int 2001 59 1211 1226 10.1046/j.1523-1755.2001.0590041211.x 11260381 (Pubitemid 32281208)
18. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. ET McCarthy R Sharma M Sharma JZ Li XL Ge KN Dileepan VJ Savin, J Am Soc Nephrol 1998 9 433 8 9513905
19. NAD(P)H oxidase mediates the endothelial barrier dysfunction induced by TNF- N Gertzberg P Neumann V Rizzo A Johnson, Am J Physiology 2004 286 37 L48
20. Role of protein phosphorylation in TNF-induced apoptosis: phosphatase inhibitors synergize with TNF to activate DNA fragmentation in normal as well as TNF-resistant U937 variants. SC Wright H Zheng J Zhong FM Torti JW Larrick, J Cell Biochem 1993 53 222 33 10.1002/jcb.240530307 8263039 (Pubitemid 23323107)
21. Regulation of proliferation, survival, and apoptosis by members of the TNF superfamily. U Gaur BB Aggerwal, Biochem Pharmacol 2003 66 1403 8 10.1016/S0006-2952(03)00490-8 14555214 (Pubitemid 38373326)
22. Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. A Ortiz C Bustos J Alonso R Alcazar MJ Lopez-Armada JJ Plaza E Gonzalez J Egido, Adv Nephrol Necker Hosp 1995 24 53 77 7572422
23. Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. D Cattran T Neogi ET McCarthy VJ Savin R Sharma, J Am Soc Nephrol 2003 4 448 53 10.1097/01.ASN.0000046960.57614.17 (Pubitemid 36150869)
24. Circulating factor increasing glomerular permeability in recurrent focal segmental glomerulosclerosis. VJ Savin R Sharma M Sharma, et al. N Engl J Med 1996 334 878 883 10.1056/NEJM199604043341402 8596570 (Pubitemid 26107345)
25. Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. VJ Savin ET McCarthy R Sharma M Sharma, Translational Research 2008 151 288 292 10.1016/j.trsl.2008.04.001 18514139
26. FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. E DeSmet JP Rioux H Ammann C Deziel S Querin, Nephrol Dial Transplant 2009 24 2938 40 10.1093/ndt/gfp278 19509024
27. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? AY Meyrier, Kidney Int 76 487 491 10.1038/ki.2009.204 19494796
28. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. DC Cattran GB Appel LA Hebert, et al. Kidney Int 1999 56 2220 6 10.1046/j.1523-1755.1999.00778.x 10594798 (Pubitemid 30004751)
29. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. MS Joy DS Gipson M Dike L Powell A Thompson S Vento A Eddy AB Fogo JB Kopp D Cattran H Trachtman, Clin J Am Soc Nephrol 2009 4 1 39 47 Epub 2008 Dec 10 10.2215/CJN.02310508 19073787
30. Phase I trial of adalimumab in focal segmental glomerulosclerosis: II. Report of the FONT (novel therapies for resistant FSGS) study group. MS Joy DS Gipson L Powell J MacHardy JC Jennette S Vento C Pan V Savin A eddy AB Fogo JB Kopp D Cattran H Trachtman, Am J Kid Dis 2010 55 50 60 10.1053/j.ajkd.2009.08. 019 19932542
31. Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. A Peyser N MacHardy F Tarapore J MacHardy L Powell DS Gipson V Savin C Pan T Kump S Vento H Trachtman, BMC Nephrol 2010 11 2 10.1186/1471-2369-11-2 20113498
32. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. MJ Atkinson A Sinha SL Hass SS Colman RN Kumar M Brod CR Rowland, Health Qual Life Outcomes 2004 2 12 10.1186/1477-7525-2-12 14987333
33. Prevalence, genetics and clinical features of patients carrying podocin mutations in steroid resistant nonfamilial focal segmental glomerulosclerosis. G Caridi R Bertelli A Carrea, et al. J Am Soc Nephrol 2001 12 2742 6 11729243 (Pubitemid 33115421)
34. The genetic basis of FSGS and steroid-resistant nephrosis. MR Pollak, Sem Nephrol 2003 23 141 146 10.1053/snep.2003.50014 (Pubitemid 36397096)
35. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephritic syndrome. RG Ruf A Lichtenberger SM Karle, et al. J Am Soc Nephrol 2004 15 722 32 10.1097/01.ASN.0000113552.59155.72 14978175 (Pubitemid 38294803)
36. Broadening the spectrum of diseases related to podocin mutations. G Caridi R Bertelli M DiDuca, et al. J Am Soc Nephrol 2003 14 1278 86 10.1097/01.ASN.0000060578.79050.E0 12707396 (Pubitemid 36519196)
37. Phase II Selection Designs. P Liu, Handbook of Statistics in Clinical Oncology Marcel Dekker, John Crowley, 2001 Chapter 6 119 127
38. Randomized phase II clinical trials. R Simon R Wittes Ellenberg, Cancer Treatment Rep 1985 69 1375 81 (Pubitemid 16163075)
39. Randomized designs for early trials of new cancer treatments - An overview. M Buyse, Drug Information Journal 2000 34 387 396 (Pubitemid 30350991)
40. Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. SM Korbet, Semin Nephrol 2003 23 219 28 10.1053/snep.2003. 50020 12704582 (Pubitemid 36397104)
41. Primum non nocere: Should adults with idiopathic FSGS receive steroids? N Franceschini SL Hogan RJ Falk, Semin Nephrol 2003 23 229 33 10.1053/snep.2003.50021 12704583 (Pubitemid 36397105)
42. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. DC Cattran P Rao, Am J Kid Dis 1998 32 72 9 10.1053/ajkd.1998.v32.pm9669427 9669427
43. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. A Tejani DH Stablein, J Am Soc Nephrol 1992 2 12 Suppl 258 S263 1498285
44. Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. P Senggutuvan JS Cameron RB Hartley, et al. Pediatr Nephrol 1990 4 21 8 10.1007/BF00858431 2206875 (Pubitemid 20057505)
45. The differential effect of race among pediatric kidney transplant recipients with focal segmental glomerulosclerosis. K Huang ME Ferris KA Andreoni DS Gipson, Am J Kidney Dis 2004 43 1082 1090 10.1053/j.ajkd.2004.03.017 15168389 (Pubitemid 38691504)
46. Treatment of primary focal segmental glomerulosclerosis. SM Korbet, Kidney Int 2002 62 2301 10 10.1046/j.1523-1755.2002.00674.x 12427162 (Pubitemid 35366191)
47. Other immunosuppressive agents for focal segmental glomerulosclerosis. C Ponticelli P Passerini, Semin Nephrol 2003 23 242 8 10.1053/snep.2003.50023 12704585 (Pubitemid 36397107)
48. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. E Selvin S Bolen HC Yeh C Wiley LM Wilson SS Marinopoulos L Feldman R Vassy J Wilson EB Bass FL Brancati, Arch Intern Med 2008 168 19 2070 80 10.1001/archinte.168.19.2070 18955635
49. Oral hypoglycaemics - a review of the evidence. PJ Phillips SM Twigg, Aust Fam Physician 2010 39 9 651 3 20877770
50. American Cancer Society Guidelines for the Early Detection of Cancer. RA Smith V Cokkinides HJ Eyre, CA Cancer J Clin 2003 53 27 43 10.3322/canjclin.53. 1.27 12568442 (Pubitemid 36163620)